Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
6 Natural products High In Vitamins,Which One Do You Like to Eat - 2Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- 3Discovery of massive spider's web in Greece reveals unexpected behavior
- 4Exploring School Life: Self-awareness and Illustrations
- 5$2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Hamas hands over another body in the Gaza Strip
- Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- Explainer-What has happened to the damaged spacecraft at China's space station?
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Well known SUVs With Low Energy Utilization In 2024
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- Get To Be familiar with The Historical backdrop Of Western Medication
